



Cancer Bio-Immunotherapy in Siena - XIth NIBIT Meeting

Siena - October 17-19, 2013

Scientific Committee: NIBIT Board of Directors

Thursday, October 17

12:00 Arrival/Registration/Light lunch

14:00 Welcome addresses

Session 1: Revisiting tumor associated mutated antigens

14:15 **Keynote Lecture:** *Paul Robbins (Bethesda, USA): "Use of high-throughput sequencing methods to identify mutated tumor antigens"

14:45 *Zlatko Trajanoski (Innsbruck, AT): "The colorectal cancer antigenome: what can we learn from next-generation sequencing data"

15:10 *Ugur Sahin (Mainz, DE): "Genomics tailored cancer immunotherapy: towards bedside"

15:35 *Paolo Dellabona (Milan, IT): "Immunogenicity of mutated antigens of colorectal cancer"

Abstract selected for oral presentation

16:00 1-2 selected abstracts (15' each including 5' discussion)

16:30 Coffee break

Session 2: Cancer stem cells and immune cells crosstalk at the metastasis forefront

- 17:00 *Iliaria Malanchi (London, GB): “Putting cancer stem cells in context”
- 17:25 *Ruggero De Maria (Rome, IT): “Therapeutic targeting of cancer stem cells”
- 17:50 *Cristina Maccalli (Milan, IT): “Immune profile of cancer stem cells of human solid tumors”
- Abstract selected for oral presentation**
- 18:15 1-2 selected abstracts (15’ each including 5’ discussion)
- 19:30 Wine and Cheese
- 21:00 General Assembly of the NIBIT

Friday, October 18

Session 3: Metabolism at the interface between immune and cancer cells

- 8:30 *Licia Rivoltini (Milan, IT): “Role of acidity in tumor immunity”
- 8:55 *Salem Chouaib (Paris, FR): “Influence of hypoxic microenvironmental stress on anti-tumor immunity”
- 9:20 *Vincenzo Bronte (Verona, IT): “Cancer metabolism and immune suppression”
- 9:45 *Barbara Seliger (Halle, DE): “Dual role of MicroRNAs on tumors by shaping immune surveillance and growth properties”

Abstract selected for oral presentation

- 10:10 2 selected abstracts (15’ each including 5’ discussion)
- 10:45 Coffee break

Session 4: Adoptive immunotherapy

- 11:30 *Robert Hawkins (Manchester, GB): “Adoptive cell therapy with natural and engineered T- cells”

11:55 *Gianpietro Dotti (Houston, USA): “Adoptive immunotherapy with CAR-modified T cells”

12:20 *Attilio Bondanza (Milan, IT): “Overcoming the toxicity hurdles of adoptive T-cell therapy”

Abstract selected for oral presentation

12:45 1-2 selected abstracts (15’ each including 5’ discussion)

13:15 **MedImmune Luncheon Satellite Symposium: Current and innovative treatment for malignant mesothelioma**

*Luciano Mutti (Vercelli, IT): “Up-dates on the biology”

*Hedy Lee Kindler (Chicago, USA): “Current therapy”

*Luana Calabrò (Siena, IT): “Anti-CTLA4 treatment”

Session 5: Immunomodulating antibodies in melanoma and beyond

15:00 *Jeffrey Weber (Tampa, USA): “Overview on immune checkpoint for cancer treatment”

15:25 *Mario Sznol (New Heaven, USA): “Immunotherapy with anti-PD1 and combinations”

15:50 TBD: “PDL1 in melanoma”

16:15 *Ignacio Melero (Pamplona, ES): “CD137-based immunotherapy of cancer: a quest for synergies based on mechanism of action”

Abstract selected for oral presentation

16:40 2 selected abstracts (15’ each including 5’ discussion)

17:10 Tea Break

Session 6: Non - profit clinical trials ongoing in Italy

17:40 *Anna Maria Di Giacomo (Siena, IT): “NIBIT-M2”

*Giorgio Parmiani (Milan, IT): “NGR/Vax/01”

*Francesco De Rosa (Meldola, IT): “AbsIDe: tricks and tips for getting approved a non-sponsored clinical study with advanced therapy medicinal products in Italy”

Abstract selected for oral presentation

18:20 1 selected abstracts (15' each including 5' discussion)

18:35 **The NIBIT Foundation round Table: the Industry, Regulatory and Academy interplay**

Under construction

20:00 Social dinner

Saturday, October 19**Session 7: Immunologic aspects of target therapy**

8:30 **Keynote Lecture:** TBD

9:00 *Paola Allavena (Milan, IT): "Inflammation during target therapy"

9:25 *Chiara Castelli (Milan, IT): "Immune modulation induced by targeted therapies in solid tumors: potential role in disease control and drug resistance"

9:50 *Soldano Ferrone (Boston, USA): "Hedgehog signal pathway in melanoma"

Abstract selected for oral presentation

10:15 1 selected abstracts (15' each including 5' discussion)

10:30 Coffee break

Session 8: Prognostic and predictive biomarkers in bio-immunotherapy

11:00 **Keynote Lecture:** *Francesco M. Marincola (Doha, Q): "The continuum of immune surveillance"

11:30 *Duccio Cavalieri (Trento, IT): "Systems biology approaches to DC"

based melanoma immunotherapy”

11:55 *Hervé Fridman (Paris, FR): “Prognostic impact of the immune microenvironment in primary and metastatic human tumors”

12:20 *Graham Pawelec (Tubingen, DE): “Correlation between antigen-specific T cells and survival in melanoma”

12:45 *Harpreet Singh (Tubingen, DE): “Actively personalized peptide vaccines for cancer therapy”

Abstract selected for oral presentation

13:10 1 selected abstracts (15’ each including 5’ discussion)

13:30 **Philogen Luncheon Satellite Symposium: Immunoconjugated monoclonal antibodies**

*Pier Adelchi Ruffini (Siena, IT): TITLE TBD

*Anas Younes (New York, USA): “Immunoconjugated monoclonal antibodies in hematological malignancies”

15:00 NIBIT AWARDS ASSIGNMENT

15:15 Adjourn

* confirmed speaker